A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers

Journal of Thoracic and Cardiovascular Surgery

Volumn 117, Issue 4, 1999, Pages 736-743

  D'Amico, T A ^a   Massey, M ^a   Herndon II, J E ^a   Moore, M B ^a   Harpole D H , Jr ^a   Benfield, J R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD GROUP A ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; SIALYLTRANSFERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032959632     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5223(99)70294-1     Document Type: Article

References (27)

1. SH Landis T Murray S Bolden PA Wingo Cancer statistics, 1998 CA Cancer J Clin 48 1998 6 29
2. CF Mountain Revisions in the International System for Staging Lung Cancer Chest 111 1997 1710 1717
3. DH Harpole Jr JE Herndon II WG Young WG Wolfe DC Sabiston Jr Stage I non–small cell lung cancer Cancer 76 1995 787 796
4. CF Mountain JM Lukeman SP Hammar Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population J Surg Oncol 35 1987 147 156
5. CF Mountain A new international staging system for lung cancer Chest 89 1986 225S 233S
6. CF Mountain Value of the new TNM staging system for lung cancer Chest 96 1989 47S 49S
7. JC Nesbitt JB Putnam Jr GL Walsh JA Roth CF Mountain Survival in early-stage non–small cell lung cancer Ann Thorac Surg 60 1995 466 472
8. Y Ichinose N Hara M Ohta T Yano K Maeda H Asoh Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non–small cell lung cancer? J Thorac Cardiovasc Surg 106 1993 90 94
9. P Macchiarini G Fontanini MJ Hardin H Chuanchieh D Bigini S Vignati Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non–small cell lung cancer J Thorac Cardiovasc Surg 106 1993 80 89
10. PA Thomas L Rubinstein Cancer recurrence after resection: T1 N0 non–small cell lung cancer Ann Thorac Surg 49 1990 242 247
11. A Takise A Kodama Y Shimosato S Watanabe K Suemasu Histopathologic prognostic factors in adenocarcinoma of the lung periphery less than 2 cm in diameter Cancer 61 1988 2083 2088
12. PC Pairolero DE Williams EJ Bergstralh JM Piehler PE Bernatz WS Payne Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease Ann Thorac Surg 38 1984 331 336
13. DH Harpole Jr WG Richards JE Herndon II DJ Sugarbaker Angiogenesis and molecular biologic substaging in patients with stage I non–small cell lung cancer Ann Thorac Surg 61 1996 1470 1476
14. DH Harpole Jr JR Marks WG Richards JE Herndon II DJ Sugarbaker Localized adenocarcinoma of the lung: oncogene expression of erb -b2 and p53 in 150 patients Clin Cancer Res 1 1995 659 664
15. DH Harpole Jr JE Herndon II WG Wolfe JD Iglehart JR Marks A prognostic model of recurrence and death in stage I non–small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression Cancer Res 55 1995 51 56
16. GM Strauss DJ Kwiatowski DH Harpole TJ Lynch AT Skarin DJ Sugarbaker Molecular and pathologic markers in stage I non–small cell carcinoma of the lung J Clin Oncol 13 1995 1265 1279
17. K Matsuyama Y Chiba M Sasaki H Tanaka R Muraoka N Tanigawa Tumor angiogenesis as a prognostic marker in operable non–small cell lung cancer Ann Thorac Surg 65 1998 1405 1409
18. PF Bongiorno RI Whyte EJ Lesser JH Moore MB Orringer DG Geer Alterations of K-ras, p53, and erb -b2/neu in human lung adenocarcinomas J Thorac Cardiovasc Surg 107 1994 590 595
19. IG Duarte BL Bufkin MF Pennington AA Gal C Cohen AS Kosinski Angiogenesis a predictor of survival after surgical resection for stage I non–small cell lung cancer J Thorac Cardiovasc Surg 115 1998 652 659
20. JA Kern DA Schwartz JE Nordberg P185neu expression in human lung adenocarcinomas predicts shortened survival Cancer Res 50 1990 5184 5191
21. DC Quinlan AG Davidson CL Summers HE Warden HM Doshi Accumulation of p53 proteins correlates with a poor prognosis in human lung cancer Cancer Res 54 1992 4828 4831
22. S Rodenhuis RJC Slebos Clinical significance of ras oncogene activation in human lung cancer Cancer Res 52 1992 2665 2669
23. H Matsumoto H Muramatsu T Shimotakahara M Yanagi H Nishijima N Mitani Correlation of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas Cancer 72 1993 75 81
24. T Terada Y Nakanuma Expression of mucin carbohydrate antigens (T, Tn, and sialyl Tn) and MUC-1 gene product in intraductal papillary mucinous neoplasms of the pancreas Am J Clin Path 105 1996 613 620
25. R Soares A Marinho F Schmitt Expression of sialyl-Tn in breast cancer: correlation with prognostic parameters Pathol Res Pract 192 1996 1181 1186
26. DJ Kwiatkowski DHH Harpole Jr J Godleski JE Herndon III DB Shieh W Richards Molecular pathologic substaging in 244 stage I non–small cell lung cancer patients: clinical implications J Clin Oncol 16 1998 2468 2477
27. F Pezzella H. Turley I Kuzu MF Tungekar MS Dunnill CB Pierce Bcl-2 protein in non–small cell lung carcinoma N Engl J Med 329 1993 690 694